RCTs are the ‘gold standard’ for determining the efﬁcacy and safety of a medicine, while real-world evidence can provide insight into the effectiveness in routine clinical practice – together, these can support treatment decisions1,3,4
ARISTOPHANES was a large-scale retrospective, US real-world analysis examining both DOAC vs. warfarin, and DOAC vs. DOAC in 434,046 propensity score - matched patients with NVAF.2
There are no head-to-head RCTs comparing the DOACs.
The results of the ARISTOPHANES real-world analysis should only be used for hypothesis generation and must be interpreted with caution, as the effectiveness and safety outcomes and assessed patient populations may be different to those in the ARISTOTLE clinical trial.
Additional real-world data studies are available. Please click GET IN TOUCH to contact your local BMS / Pﬁzer representative for more information.
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.8
Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie